Dejeu, D.; Dejeu, P.; Muresan, A.; Bradea, P.; Dejeu, V.
Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review. Biomedicines 2025, 13, 752.
https://doi.org/10.3390/biomedicines13030752
AMA Style
Dejeu D, Dejeu P, Muresan A, Bradea P, Dejeu V.
Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review. Biomedicines. 2025; 13(3):752.
https://doi.org/10.3390/biomedicines13030752
Chicago/Turabian Style
Dejeu, Danut, Paula Dejeu, Anita Muresan, Paula Bradea, and Viorel Dejeu.
2025. "Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review" Biomedicines 13, no. 3: 752.
https://doi.org/10.3390/biomedicines13030752
APA Style
Dejeu, D., Dejeu, P., Muresan, A., Bradea, P., & Dejeu, V.
(2025). Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review. Biomedicines, 13(3), 752.
https://doi.org/10.3390/biomedicines13030752
